Development of Antibody-Based Therapeutics: Translational Considerations
Development of Antibody-Based Therapeutics: Translational Considerations examines important considerations necessary for the design of effective translational strategies during the development of antibody-based therapeutics. Translational strategies for development of antibody-based therapeutics req...
Gespeichert in:
| Weitere Verfasser: | , , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
New York, NY
Springer New York
2012
|
| Ausgabe: | 1st ed. 2012 |
| Schlagworte: | |
| Online-Zugang: | UBR01 Volltext |
| Zusammenfassung: | Development of Antibody-Based Therapeutics: Translational Considerations examines important considerations necessary for the design of effective translational strategies during the development of antibody-based therapeutics. Translational strategies for development of antibody-based therapeutics require an understanding of the relationship between the 'unit dose' and 'unit effect' with respect to both beneficial and deleterious biological effects from early stages of development. The flow of information across various stages of development should provide opportunities to facilitate selection of more effective novel and next-generation drug candidates. Successful strategies for the development of monoclonal antibodies require integration of knowledge with regards to target antigen properties in health and disease, as well as antibody design criteria including affinity, isotype selection, pharmacokinetics/pharmacodynamics (PK/PD) properties, antibody cross-reactivity across species, and safety. Selection and evaluation of appropriate biomarkers in early preclinical development in "relevant" animal models should allow identification of potential risks and liabilities of an antibody drug candidate to humans and establishment of safe First-In-Human (FIH) dosing strategies. This volume provides a comprehensive review of the topics critical for establishing successful translational strategies for the development of antibody-based therapeutics |
| Beschreibung: | 1 Online-Ressource (XIV, 426 Seiten) |
| ISBN: | 9781441959553 |
| DOI: | 10.1007/978-1-4419-5955-3 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV047942926 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 220414s2012 |||| o||u| ||||||eng d | ||
| 020 | |a 9781441959553 |9 978-1-4419-5955-3 | ||
| 024 | 7 | |a 10.1007/978-1-4419-5955-3 |2 doi | |
| 035 | |a (ZDB-2-SME)978-1-4419-5955-3 | ||
| 035 | |a (OCoLC)1312698929 | ||
| 035 | |a (DE-599)BVBBV047942926 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 615.1 |2 23 | |
| 084 | |a VS 9400 |0 (DE-625)147728:253 |2 rvk | ||
| 245 | 1 | 0 | |a Development of Antibody-Based Therapeutics |b Translational Considerations |c edited by Mohammad A. Tabrizi, Gadi G. Bornstein, Scott L. Klakamp |
| 250 | |a 1st ed. 2012 | ||
| 264 | 1 | |a New York, NY |b Springer New York |c 2012 | |
| 300 | |a 1 Online-Ressource (XIV, 426 Seiten) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 520 | |a Development of Antibody-Based Therapeutics: Translational Considerations examines important considerations necessary for the design of effective translational strategies during the development of antibody-based therapeutics. Translational strategies for development of antibody-based therapeutics require an understanding of the relationship between the 'unit dose' and 'unit effect' with respect to both beneficial and deleterious biological effects from early stages of development. The flow of information across various stages of development should provide opportunities to facilitate selection of more effective novel and next-generation drug candidates. Successful strategies for the development of monoclonal antibodies require integration of knowledge with regards to target antigen properties in health and disease, as well as antibody design criteria including affinity, isotype selection, pharmacokinetics/pharmacodynamics (PK/PD) properties, antibody cross-reactivity across species, and safety. Selection and evaluation of appropriate biomarkers in early preclinical development in "relevant" animal models should allow identification of potential risks and liabilities of an antibody drug candidate to humans and establishment of safe First-In-Human (FIH) dosing strategies. This volume provides a comprehensive review of the topics critical for establishing successful translational strategies for the development of antibody-based therapeutics | ||
| 650 | 4 | |a Pharmacy | |
| 650 | 4 | |a Pharmacology/Toxicology | |
| 650 | 4 | |a Biochemistry, general | |
| 650 | 4 | |a Pharmacy | |
| 650 | 4 | |a Pharmacology | |
| 650 | 4 | |a Biochemistry | |
| 650 | 0 | 7 | |a Antikörper |0 (DE-588)4002290-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittelentwicklung |0 (DE-588)4143176-5 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Antikörper |0 (DE-588)4002290-0 |D s |
| 689 | 0 | 1 | |a Arzneimittelentwicklung |0 (DE-588)4143176-5 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Tabrizi, Mohammad A. |4 edt | |
| 700 | 1 | |a Bornstein, Gadi G. |4 edt | |
| 700 | 1 | |a Klakamp, Scott L. |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781441959645 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781441959539 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781489991133 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-1-4419-5955-3 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_2012 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-033324381 | ||
| 966 | e | |u https://doi.org/10.1007/978-1-4419-5955-3 |l UBR01 |p ZDB-2-SME |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804183589849399296 |
|---|---|
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| author2 | Tabrizi, Mohammad A. Bornstein, Gadi G. Klakamp, Scott L. |
| author2_role | edt edt edt |
| author2_variant | m a t ma mat g g b gg ggb s l k sl slk |
| author_facet | Tabrizi, Mohammad A. Bornstein, Gadi G. Klakamp, Scott L. |
| building | Verbundindex |
| bvnumber | BV047942926 |
| classification_rvk | VS 9400 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-1-4419-5955-3 (OCoLC)1312698929 (DE-599)BVBBV047942926 |
| dewey-full | 615.1 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.1 |
| dewey-search | 615.1 |
| dewey-sort | 3615.1 |
| dewey-tens | 610 - Medicine and health |
| discipline | Chemie / Pharmazie Medizin |
| discipline_str_mv | Chemie / Pharmazie Medizin |
| doi_str_mv | 10.1007/978-1-4419-5955-3 |
| edition | 1st ed. 2012 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03492nmm a2200565zc 4500</leader><controlfield tag="001">BV047942926</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">220414s2012 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781441959553</subfield><subfield code="9">978-1-4419-5955-3</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-1-4419-5955-3</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-1-4419-5955-3</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1312698929</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV047942926</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.1</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VS 9400</subfield><subfield code="0">(DE-625)147728:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Development of Antibody-Based Therapeutics</subfield><subfield code="b">Translational Considerations</subfield><subfield code="c">edited by Mohammad A. Tabrizi, Gadi G. Bornstein, Scott L. Klakamp</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1st ed. 2012</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York, NY</subfield><subfield code="b">Springer New York</subfield><subfield code="c">2012</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XIV, 426 Seiten)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Development of Antibody-Based Therapeutics: Translational Considerations examines important considerations necessary for the design of effective translational strategies during the development of antibody-based therapeutics. Translational strategies for development of antibody-based therapeutics require an understanding of the relationship between the 'unit dose' and 'unit effect' with respect to both beneficial and deleterious biological effects from early stages of development. The flow of information across various stages of development should provide opportunities to facilitate selection of more effective novel and next-generation drug candidates. Successful strategies for the development of monoclonal antibodies require integration of knowledge with regards to target antigen properties in health and disease, as well as antibody design criteria including affinity, isotype selection, pharmacokinetics/pharmacodynamics (PK/PD) properties, antibody cross-reactivity across species, and safety. Selection and evaluation of appropriate biomarkers in early preclinical development in "relevant" animal models should allow identification of potential risks and liabilities of an antibody drug candidate to humans and establishment of safe First-In-Human (FIH) dosing strategies. This volume provides a comprehensive review of the topics critical for establishing successful translational strategies for the development of antibody-based therapeutics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacology/Toxicology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biochemistry, general</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biochemistry</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Antikörper</subfield><subfield code="0">(DE-588)4002290-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelentwicklung</subfield><subfield code="0">(DE-588)4143176-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Antikörper</subfield><subfield code="0">(DE-588)4002290-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Arzneimittelentwicklung</subfield><subfield code="0">(DE-588)4143176-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tabrizi, Mohammad A.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bornstein, Gadi G.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Klakamp, Scott L.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781441959645</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781441959539</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781489991133</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-1-4419-5955-3</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_2012</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-033324381</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-1-4419-5955-3</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV047942926 |
| illustrated | Not Illustrated |
| index_date | 2024-07-03T19:35:40Z |
| indexdate | 2024-07-10T09:25:51Z |
| institution | BVB |
| isbn | 9781441959553 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-033324381 |
| oclc_num | 1312698929 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (XIV, 426 Seiten) |
| psigel | ZDB-2-SME ZDB-2-SME_2012 |
| publishDate | 2012 |
| publishDateSearch | 2012 |
| publishDateSort | 2012 |
| publisher | Springer New York |
| record_format | marc |
| spelling | Development of Antibody-Based Therapeutics Translational Considerations edited by Mohammad A. Tabrizi, Gadi G. Bornstein, Scott L. Klakamp 1st ed. 2012 New York, NY Springer New York 2012 1 Online-Ressource (XIV, 426 Seiten) txt rdacontent c rdamedia cr rdacarrier Development of Antibody-Based Therapeutics: Translational Considerations examines important considerations necessary for the design of effective translational strategies during the development of antibody-based therapeutics. Translational strategies for development of antibody-based therapeutics require an understanding of the relationship between the 'unit dose' and 'unit effect' with respect to both beneficial and deleterious biological effects from early stages of development. The flow of information across various stages of development should provide opportunities to facilitate selection of more effective novel and next-generation drug candidates. Successful strategies for the development of monoclonal antibodies require integration of knowledge with regards to target antigen properties in health and disease, as well as antibody design criteria including affinity, isotype selection, pharmacokinetics/pharmacodynamics (PK/PD) properties, antibody cross-reactivity across species, and safety. Selection and evaluation of appropriate biomarkers in early preclinical development in "relevant" animal models should allow identification of potential risks and liabilities of an antibody drug candidate to humans and establishment of safe First-In-Human (FIH) dosing strategies. This volume provides a comprehensive review of the topics critical for establishing successful translational strategies for the development of antibody-based therapeutics Pharmacy Pharmacology/Toxicology Biochemistry, general Pharmacology Biochemistry Antikörper (DE-588)4002290-0 gnd rswk-swf Arzneimittelentwicklung (DE-588)4143176-5 gnd rswk-swf Antikörper (DE-588)4002290-0 s Arzneimittelentwicklung (DE-588)4143176-5 s DE-604 Tabrizi, Mohammad A. edt Bornstein, Gadi G. edt Klakamp, Scott L. edt Erscheint auch als Druck-Ausgabe 9781441959645 Erscheint auch als Druck-Ausgabe 9781441959539 Erscheint auch als Druck-Ausgabe 9781489991133 https://doi.org/10.1007/978-1-4419-5955-3 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Development of Antibody-Based Therapeutics Translational Considerations Pharmacy Pharmacology/Toxicology Biochemistry, general Pharmacology Biochemistry Antikörper (DE-588)4002290-0 gnd Arzneimittelentwicklung (DE-588)4143176-5 gnd |
| subject_GND | (DE-588)4002290-0 (DE-588)4143176-5 |
| title | Development of Antibody-Based Therapeutics Translational Considerations |
| title_auth | Development of Antibody-Based Therapeutics Translational Considerations |
| title_exact_search | Development of Antibody-Based Therapeutics Translational Considerations |
| title_exact_search_txtP | Development of Antibody-Based Therapeutics Translational Considerations |
| title_full | Development of Antibody-Based Therapeutics Translational Considerations edited by Mohammad A. Tabrizi, Gadi G. Bornstein, Scott L. Klakamp |
| title_fullStr | Development of Antibody-Based Therapeutics Translational Considerations edited by Mohammad A. Tabrizi, Gadi G. Bornstein, Scott L. Klakamp |
| title_full_unstemmed | Development of Antibody-Based Therapeutics Translational Considerations edited by Mohammad A. Tabrizi, Gadi G. Bornstein, Scott L. Klakamp |
| title_short | Development of Antibody-Based Therapeutics |
| title_sort | development of antibody based therapeutics translational considerations |
| title_sub | Translational Considerations |
| topic | Pharmacy Pharmacology/Toxicology Biochemistry, general Pharmacology Biochemistry Antikörper (DE-588)4002290-0 gnd Arzneimittelentwicklung (DE-588)4143176-5 gnd |
| topic_facet | Pharmacy Pharmacology/Toxicology Biochemistry, general Pharmacology Biochemistry Antikörper Arzneimittelentwicklung |
| url | https://doi.org/10.1007/978-1-4419-5955-3 |
| work_keys_str_mv | AT tabrizimohammada developmentofantibodybasedtherapeuticstranslationalconsiderations AT bornsteingadig developmentofantibodybasedtherapeuticstranslationalconsiderations AT klakampscottl developmentofantibodybasedtherapeuticstranslationalconsiderations |